Qilu nabs a new B7-H3 contender
Minghui’s MHB088C will soon start phase 3 in China.
Amgen takes Imdelltra front line
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
AACR 2025 preview – new preclincal approaches abound
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
MediLink beats Sotio to the punch
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
Zai Lab looks towards an accelerated pathway
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
